Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

A Phase 2, Multicenter, Open-Label Study of Anti-Lag-3 Ieramilimab in Combination with Anti-Pd-1 Spartalizumab in Patients with Advanced Solid Malignancies

Chia-Chi Lin,Elena Garralda,Patrick Schoeffski,David S. Hong,Lillian L. Siu,Miguel Martin,Michela Maur,Rina Hui,Ross A. Soo,Joanne Chiu,Tian Zhang,Brigette Ma,Chrisann Kyi,Daniel S. W. Tan,Philippe A. Cassier,John Sarantopoulos,Andrew Weickhardt,Richard D. Carvajal,Jennifer Spratlin,Taito Esaki,Frederic Rolland,Wallace Akerley,Barbara Deschler-Baier,Lawrence Rispoli,Tanay S. Samant,Niladri Roy Chowdhury,Daniel Gusenleitner,Eunice L. Kwak,Vasileios Askoxylakis,Filippo De Braud

ONCOIMMUNOLOGY（2024）

Cited 4|Views74
Key words
Efficacy,ieramilimab,LAG-3 inhibitor,safety,spartalizumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined